JP2024531477A5 - - Google Patents
Info
- Publication number
- JP2024531477A5 JP2024531477A5 JP2024513014A JP2024513014A JP2024531477A5 JP 2024531477 A5 JP2024531477 A5 JP 2024531477A5 JP 2024513014 A JP2024513014 A JP 2024513014A JP 2024513014 A JP2024513014 A JP 2024513014A JP 2024531477 A5 JP2024531477 A5 JP 2024531477A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- hydrogen
- alkyl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111000443 | 2021-08-27 | ||
| CN202111000443.7 | 2021-08-27 | ||
| CN202111447991 | 2021-11-30 | ||
| CN202111447991.4 | 2021-11-30 | ||
| CN202210274490.9 | 2022-03-18 | ||
| CN202210274490 | 2022-03-18 | ||
| PCT/CN2022/115259 WO2023025307A1 (en) | 2021-08-27 | 2022-08-26 | Substituted tricyclic compounds as parp inhibitors and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024531477A JP2024531477A (ja) | 2024-08-29 |
| JP2024531477A5 true JP2024531477A5 (https=) | 2025-08-20 |
Family
ID=85322483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513014A Pending JP2024531477A (ja) | 2021-08-27 | 2022-08-26 | Ｐａｒｐ阻害剤としての置換三環式化合物およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240368169A1 (https=) |
| EP (1) | EP4392425A4 (https=) |
| JP (1) | JP2024531477A (https=) |
| KR (1) | KR20240053612A (https=) |
| CN (1) | CN117980307A (https=) |
| AU (1) | AU2022334408A1 (https=) |
| CA (1) | CA3230491A1 (https=) |
| IL (1) | IL311024A (https=) |
| MX (1) | MX2024002425A (https=) |
| WO (1) | WO2023025307A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102867210B1 (ko) | 2021-10-01 | 2025-10-14 | 신테라, 인크. | 아제티딘 및 피롤리딘 parp1 저해제, 및 이의 용도 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| CN119013279A (zh) * | 2022-03-11 | 2024-11-22 | 上海瑛派药业有限公司 | 作为parp抑制剂的取代的三环类化合物及其应用 |
| AU2023235233A1 (en) | 2022-03-14 | 2024-09-12 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AU2023259236B2 (en) | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| JP7835895B2 (ja) * | 2022-05-07 | 2026-03-25 | サイブランチ セラピューティクス カンパニー リミテッド | Ｐａｒｐ１を選択的に阻害するフルオロキノキサリノン誘導体 |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| CN117263943A (zh) * | 2022-09-09 | 2023-12-22 | 轩竹生物科技股份有限公司 | 聚（adp核糖）聚合酶选择性抑制剂 |
| WO2024099416A1 (zh) * | 2022-11-10 | 2024-05-16 | 上海海和药物研究开发股份有限公司 | 一种稠合三环类parp1抑制剂、其制备方法及用途 |
| WO2024255697A1 (zh) * | 2023-06-13 | 2024-12-19 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| TW202525808A (zh) * | 2023-09-13 | 2025-07-01 | 大陸商上海瑛派藥業有限公司 | 用作ｐａｒｐ１抑制劑的化合物、其用途及包含其之組合物 |
| CN117567473B (zh) * | 2023-11-09 | 2025-07-04 | 中国药科大学 | 一种靶向同源二聚体的抑制剂及其制备方法与应用 |
| AR134686A1 (es) * | 2023-12-13 | 2026-03-04 | Eikon Therapeutics Inc | Síntesis novedosa de compuestos tricíclicos sustituidos |
| CN120923504A (zh) | 2024-05-09 | 2025-11-11 | 上海瑛派药业有限公司 | Parp1抑制剂的晶型及其制备 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| CA2672860C (en) | 2006-12-28 | 2013-01-29 | Abbott Laboratories | Inhibitors of poly(adp-ribose)polymerase |
| CN101981013B (zh) | 2008-03-27 | 2013-05-29 | 詹森药业有限公司 | 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮 |
| CN102341394B (zh) * | 2009-01-23 | 2015-04-15 | 武田药品工业株式会社 | 聚(adp-核糖)聚合酶(parp)抑制剂 |
| JP5744019B2 (ja) | 2009-07-14 | 2015-07-01 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 選択的ｐａｒｐ−１阻害を有する３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−カルボキサミド |
| EP2459561A1 (en) * | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| JP5902299B2 (ja) | 2011-07-26 | 2016-04-13 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｐａｒｐ−１阻害剤としての３−オキソ−２，３−ジヒドロ−１ｈ−インダゾール−４−カルボキサミド誘導体 |
| MX375707B (es) * | 2015-06-09 | 2025-03-06 | Onconic Therapeutics Inc | Compuesto derivativo triciclico, metodo para prepararlo y composicion farmaceutica que comprende el mismo. |
| GB201800733D0 (en) * | 2018-01-17 | 2018-02-28 | Cambridge Entpr Ltd | Cancer |
| SI3999506T1 (sl) | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| CN112028829B (zh) * | 2020-09-25 | 2022-02-15 | 温州大学 | 一种合成菲啶酮类化合物的方法 |
| US11591331B2 (en) * | 2021-04-19 | 2023-02-28 | Xinthera, Inc. | PARP1 inhibitors and uses thereof |
| AU2023259236B2 (en) * | 2022-04-28 | 2025-01-09 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
-
2022
- 2022-08-26 AU AU2022334408A patent/AU2022334408A1/en active Pending
- 2022-08-26 WO PCT/CN2022/115259 patent/WO2023025307A1/en not_active Ceased
- 2022-08-26 JP JP2024513014A patent/JP2024531477A/ja active Pending
- 2022-08-26 US US18/687,111 patent/US20240368169A1/en active Pending
- 2022-08-26 IL IL311024A patent/IL311024A/en unknown
- 2022-08-26 MX MX2024002425A patent/MX2024002425A/es unknown
- 2022-08-26 EP EP22860653.9A patent/EP4392425A4/en active Pending
- 2022-08-26 CN CN202280058269.8A patent/CN117980307A/zh active Pending
- 2022-08-26 KR KR1020247010055A patent/KR20240053612A/ko active Pending
- 2022-08-26 CA CA3230491A patent/CA3230491A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024531477A5 (https=) | ||
| UA126421C2 (uk) | Інгібітори pd-1/pd-l1 | |
| JP2022507025A5 (https=) | ||
| RU2018130330A (ru) | Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией | |
| CN108430473B (zh) | 抗增殖化合物以及其药物组合物和用途 | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP2017520607A5 (https=) | ||
| JP2021529172A5 (https=) | ||
| CA3068591A1 (en) | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide | |
| JP2015536994A5 (https=) | ||
| CN107864625A (zh) | 含有取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉的组合产品 | |
| JP2025508122A5 (https=) | ||
| KR20200105662A (ko) | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 동위 이성질체 | |
| JP2024513538A5 (https=) | ||
| KR102936318B1 (ko) | 소세포폐암의 병용 치료용 퀴놀린 유도체 | |
| JP7293108B2 (ja) | Ａｘｌ阻害剤とＥＧＦＲチロシンキナーゼ阻害薬との併用治療法 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| JP2025513877A (ja) | 新規なｇｓｐｔ１化合物およびその新規な化合物の使用方法 | |
| KR20240124921A (ko) | 약학적 조성물 및 이의 용도 | |
| US20260041693A1 (en) | Combination therapy of cdk7 inhibitors with other anti-cancer therapies | |
| CN121218988A (zh) | 治疗未接受bcl2抑制剂的受试者的癌症的方法 | |
| WO2018215282A1 (en) | Combination of bub1 and pi3k inhibitors | |
| US11684672B2 (en) | Combinations of copanlisib with anti-PD-1 antibody | |
| CN113750096A (zh) | 用于治疗外周t细胞淋巴瘤的喹啉衍生物 | |
| US20240342157A1 (en) | Bak activators, pharmaceutical compositions, and uses in treating cancer |